<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's-type <z:hpo ids='HP_0001909'>leukemias</z:hpo> have specific cytologic, immunologic, and cytogenetic characteristics </plain></SENT>
<SENT sid="1" pm="."><plain>Initial symptomatology frequently includes <z:e sem="disease" ids="C0000735" disease_type="Neoplastic Process" abbrv="">abdominal tumors</z:e> and initial <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement </plain></SENT>
<SENT sid="2" pm="."><plain>Despite intensive treatment including high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, prognosis remains poor in most patients because of failures to achieve complete remission (CR) or because of early relapses, especially <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapses </plain></SENT>
<SENT sid="3" pm="."><plain>Class III <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> in children is defined by the presence of two or more unfavorable parameters and recent progress has been achieved by intensive therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Cox's multifactorial analysis allows improved discrimination </plain></SENT>
<SENT sid="5" pm="."><plain>A phase I protocol for increased-risk <z:hpo ids='HP_0001909'>leukemias</z:hpo>, including testis preventive irradiation and monthly reinductions without continuous maintenance for the first 6 months of CR, seems promising </plain></SENT>
</text></document>